Related Experiment Videos
Current indications for ACE inhibitors and HOPE for the future
1Heartland Health, St Joseph, MO 65406-3398, USA. stephanie.burch@mail.heartland-health.com
The American Journal of Managed Care
|May 22, 2002
Summary
Angiotensin-converting enzyme (ACE) inhibitors are proven effective for heart failure, myocardial infarction, and diabetes. Recent trials suggest ACE inhibitors may also benefit primary prevention of coronary artery disease.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Angiotensin-converting enzyme (ACE) inhibitors are established treatments for cardiovascular and metabolic diseases.
- Their efficacy in congestive heart failure, myocardial infarction, and diabetes is well-documented.
Purpose of the Study:
- To review the clinical use, efficacy, and cost-effectiveness of ACE inhibitors.
- To evaluate the emerging role of ACE inhibitors in the primary prevention of coronary artery disease.
Main Methods:
- Review of existing clinical trial data and evidence.
- Analysis of findings from major trials like the Heart Outcomes Prevention Evaluation (HOPE) trial.
Main Results:
- ACE inhibitors demonstrate significant efficacy across multiple disease states.
- The HOPE trial indicates a potential benefit of ACE inhibitors in primary prevention of coronary artery disease.
Conclusions:
- ACE inhibitors are valuable agents in managing established cardiovascular and diabetic conditions.
- Further research and ongoing trials are essential to fully define the role of ACE inhibitors in coronary artery disease prevention.